No products approved for commercial sale
The company has a limited operating history and depends on pipeline success to create revenue.
- Scope
- Entire business model
- Materiality
- high
Compass Therapeutics, Inc.
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies. Its pipeline centers on bispecific and other proprietary antibodies designed to disrupt angiogenesis and tumor biology, with lead programs including tovecimig, CTX-471, CTX-8371, and CTX-10726.
−100,0 %
15.02
15.02
| % | |
|---|---|
| Clinical-stage oncology programs | 85% Lead and follow-on antibody candidates being advanced through clinical and IND-enabling development. |
| Platform technology | 10% StitchMabsTM and related antibody discovery/engineering capabilities used to create bispecifics. |
| Licensing and collaboration revenue | 5% Milestones and other payments from partners for licensed product rights and development progress. |
Compass Therapeutics does not yet sell approved products; its current economic counterparties are licensing partners,...
- Licensing and collaboration partnersprimary
Biopharma partners that pay milestones or royalties for rights to selected programs or geographies.
- Clinical trial ecosystemprimary
Hospitals, investigators, CROs, and vendors that support development of product candidates.
- Future oncology prescriberssecondary
Physicians and cancer centers that would use approved products if the pipeline reaches market.
- Third-party payorssecondary
Insurers and reimbursement bodies that would influence uptake and net access after approval.
Compass Therapeutics is headquartered in Boston, Massachusetts and operates as a U.S.-based clinical-stage company with...
- •Headquartered in Boston, Massachusetts
- •Clinical development and corporate functions are U.S.-based
- •Worldwide rights to most product candidates support global partnering
- •China milestone revenue came from Elpiscience for Phase 1 completion
- •Third-party manufacturing and trials may occur in multiple countries
The company is focused on advancing its antibody pipeline through clinical development while preserving optionality to...
01
Advance the clinical pipelineshort-term
Clinical data and regulatory progress are the main value drivers for a pre-revenue biotech.
02
Maintain partnering optionalitymedium-term
Regional or program-level deals can fund development and reduce capital burden.
03
Extend cash runwayshort-term
The company expects to need substantial additional funding before product sales.
Compass Therapeutics is a pre-commercial biotech with no approved products, so its value depends on successful clinical...
Need for additional capital
R&D spending exceeds revenue and the company may need equity, debt, or partnerships to fund operations.
- Scope
- Cash runway and development continuity
- Materiality
- high
Third-party trial and manufacturing dependence
The company relies on CROs and contract manufacturers for clinical studies and supply.
- Scope
- Development timelines and regulatory readiness
- Materiality
- high
Intellectual property competition
Biotech competitors and larger pharma companies may develop similar oncology assets or challenge IP.
- Scope
- Pipeline differentiation and partnering leverage
- Materiality
- medium
Cybersecurity and data privacy
Research data, IP, and personal information are stored digitally and may be targeted or disrupted.
- Scope
- Confidential data and operational continuity
- Materiality
- medium
Research and development expense accruals
Can shift expense timing between periods
Milestone-based licensing revenue
Can materially affect quarterly comparability
Stock-based compensation
Affects operating loss and non-cash expense profile
Operating lease commitments
Affects liquidity analysis and future cash outflows
AMICUS THERAPEUTICS, INC.
Pharmaceutical Preparations
Maze Therapeutics, Inc.
MAZE · Biological Products, (No Diagnostic Substances)
COMPASS Pathways plc
CMPS · Pharmaceutical Preparations
COMPASS Pathways plc is a clinical-stage biotechnology company focused on developing COMP360, a proprietary pharmaceutical-grade psilocybin treatment for serious mental health conditions.
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Century Therapeutics, Inc.
IPSC · Biological Products, (No Diagnostic Substances)
: 28.4.2026